Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Relugolix

FDA-approved product (tablet, oral), marketed as Orgovyx.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Relugolix
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
FDA pharmacologic class
Gonadotropin Releasing Hormone Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Relugolix in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Relugolix with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

    NCT07751133 · start 2026-08-28

    Registered record
    Registry ID
    NCT07751133
    Conditions
    Prostate Cancer; mHSPC; mCRPC
    Interventions
    Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-08-28
    Completion
    2033-08-01
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; mHSPC; mCRPC
    InterventionAbiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy
    PhasePhase 3
    Registry statusRecruiting

  • Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

    NCT07801664 · start 2026-08-06

    Registered record
    Registry ID
    NCT07801664
    Conditions
    Prostate Cancer
    Interventions
    Androgen Deprivation Therapy (ADT); Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-06
    Completion
    2029-08-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAndrogen Deprivation Therapy (ADT); Radiotherapy
    PhasePhase 2
    Registry statusRecruiting

  • Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

    NCT07142551 · start 2026-03-09

    Registered record
    Registry ID
    NCT07142551
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    Testosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; Darolutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-03-09
    Completion
    2034-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionTestosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; Darolutamide
    PhasePhase 2
    Registry statusRecruiting

  • REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)

    NCT07302451 · start 2026-02-23

    Registered record
    Registry ID
    NCT07302451
    Conditions
    Prostate Cancer (Adenocarcinoma)
    Interventions
    Combined Androgen Deprivation Therapy with Relugolix and Image-Guided Stereotactic Body Radiotherapy (SBRT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-02-23
    Completion
    2031-02-23
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Adenocarcinoma)
    InterventionCombined Androgen Deprivation Therapy with Relugolix and Image-Guided Stereotactic Body Radiotherapy (SBRT)
    PhasePhase 2
    Registry statusRecruiting

  • Insights in Endocervical Mucus Secretion

    NCT07111247 · start 2026-01-02

    Registered record
    Registry ID
    NCT07111247
    Conditions
    Cervical Mucus
    Interventions
    Gonadotropin Releasing Hormone Antagonists Relugolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-01-02
    Completion
    2027-08
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Mucus
    InterventionGonadotropin Releasing Hormone Antagonists Relugolix
    PhasePhase 4
    Registry statusRecruiting

  • Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

    NCT07100782 · start 2025-12-08

    Registered record
    Registry ID
    NCT07100782
    Conditions
    Endometriosis; Pelvic Pain
    Interventions
    Relugolix CT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-08
    Completion
    2028-09
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Pelvic Pain
    InterventionRelugolix CT
    PhasePhase 3
    Registry statusRecruiting

  • Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

    NCT07025369 · start 2025-08-25

    Registered record
    Registry ID
    NCT07025369
    Conditions
    Prostate Adenocarcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8
    Interventions
    Biospecimen Collection; Computed Tomography; Flotufolastat F-18 Gallium; Laparoscopic Radical Prostatectomy with Robotics; Pelvic Lymphadenectomy; Positron Emission Tomography; Relugolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-25
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8
    InterventionBiospecimen Collection; Computed Tomography; Flotufolastat F-18 Gallium; Laparoscopic Radical Prostatectomy with Robotics +3 more
    PhasePhase 2
    Registry statusRecruiting

  • The COSMYC Trial (COmbined Suppression of MYC)

    NCT06922318 · start 2025-08-19

    Registered record
    Registry ID
    NCT06922318
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    ZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-19
    Completion
    2031-08-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    PhasePhase 2
    Registry statusRecruiting

  • Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

    NCT07182279 · start 2025-08-01

    Registered record
    Registry ID
    NCT07182279
    Conditions
    Prostate Cancer (Adenocarcinoma)
    Interventions
    Brachytherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2026-11-14
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Adenocarcinoma)
    InterventionBrachytherapy
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study

    NCT06953076 · start 2025-05-02

    Registered record
    Registry ID
    NCT06953076
    Conditions
    Uterine Bleeding; Uterine Leiomyomas; Uterine Hemorrhage; Uterine Neoplasms
    Interventions
    Relugolix/estradiol/norethisterone acetate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-05-02
    Completion
    2027-05-02
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Bleeding; Uterine Leiomyomas; Uterine Hemorrhage; Uterine Neoplasms
    InterventionRelugolix/estradiol/norethisterone acetate
    PhaseNot recorded
    Registry statusRecruiting

  • MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

    NCT05739136 · start 2025-04-30

    Registered record
    Registry ID
    NCT05739136
    Conditions
    Pregnancy Related; Pregnancy Complications; Pregnancy, High Risk
    Interventions
    Relugolix + Estradiol + Norethindrone Acetate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-04-30
    Completion
    2027-05
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy Related; Pregnancy Complications; Pregnancy, High Risk
    InterventionRelugolix + Estradiol + Norethindrone Acetate
    PhaseNot recorded
    Registry statusActive not recruiting

  • Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

    NCT06528210 · start 2025-04-16

    Registered record
    Registry ID
    NCT06528210
    Conditions
    High Risk Prostate Carcinoma; Localized Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8
    Interventions
    Gonadotropin Releasing Hormone Agonists and Antagonists; Bicalutamide; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Pembrolizumab; Questionnaire Administration; Radiation Therapy; Bone Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-04-16
    Completion
    2028-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Risk Prostate Carcinoma; Localized Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8 +1 more
    InterventionGonadotropin Releasing Hormone Agonists and Antagonists; Bicalutamide; Biopsy Procedure; Biospecimen Collection +6 more
    PhasePhase 2
    Registry statusWithdrawn

  • REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

    NCT06650579 · start 2025-01-31

    Registered record
    Registry ID
    NCT06650579
    Conditions
    Recurrent Prostate Carcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Abiraterone Acetate; Bicalutamide; Biospecimen Collection; Computed Tomography Angiography; Leuprolide; Prednisone; Radiation Therapy; Relugolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-31
    Completion
    2029-07-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Carcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionAbiraterone Acetate; Bicalutamide; Biospecimen Collection; Computed Tomography Angiography +4 more
    PhasePhase 3
    Registry statusRecruiting

  • Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

    NCT06130995 · start 2024-12-26

    Registered record
    Registry ID
    NCT06130995
    Conditions
    Androgen Deprivation Therapy; Locally Advanced Prostate Cancer
    Interventions
    Relugolix and Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-12-26
    Completion
    2030-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogen Deprivation Therapy; Locally Advanced Prostate Cancer
    InterventionRelugolix and Enzalutamide
    PhasePhase 1
    Registry statusRecruiting

  • Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

    NCT06463457 · start 2024-12-13

    Registered record
    Registry ID
    NCT06463457
    Conditions
    Prostate Cancer; Advanced Prostate Cancer; Hormone Sensitive Prostate Cancer
    Interventions
    Darolutamide; Relugolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-12-13
    Completion
    2028-11-30
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Advanced Prostate Cancer; Hormone Sensitive Prostate Cancer
    InterventionDarolutamide; Relugolix
    PhasePhase 2
    Registry statusActive not recruiting